Summary
Using considerably improved analytical methods, the kinetics and effects of clonidine were observed in healthy volunteers over periods of time more than 3 times longer than those previously reported. The high sensitivity and small work load of the newly developed method permitted the performance of low-dose and multipledose trials. 1. The complete bioavailability of clonidine and its elimination half-life (20 to 25.5 h) remained constant after single and multiple doses. 2. Approximately 62% of a given dose was excreted unchanged in the urine, independent of the quantity administered (0.075, 0.15, 0.2, 0.25 or 0.3 mg), the drug formulation (solution, tablet, Perlonget) or of the mode of administration (i.v., p.o.; single or multiple doses). 3. As the pharmacokinetics of the drug were affected by entero-hepatic circulation, it cannot be described by a conventional, open one or two compartment model. 4. The time courses of the plasma clonidine concentration and its drug effects ran asynchronously. 5. On cessation of chronic clonidine administration, blood pressure and plasma catecholamine levels increased to pretreatment levels without exhibiting any “overshoot” reaction.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Hoefke W (1980) Clonidine. In: Scriabine A (ed) Pharmacology of antihypertensive drugs. Raven Press, New York
Houston MC (1981) Clonidine hydrochloride: review of pharmacological and clinical aspects. Prog Cardiovasc Dis 23: 337–350
Arndt SD, Stähle H, Förster HJ (1981a) Development of a RIA for clonidine and its comparison with the reference methods. J Pharmacol Methods 6: 295–307
Dollery CT, Davies DS, Draffan GH, Dargie HJ, Dean CR, Reid JL, Clare RA, Murray S (1976) Clinical pharmacology and pharmacokinetics of clonidine. Clin Pharmacol Ther 19: 11–17
Frisk-Holmberg M, Edlund PO, Paalzow L (1978) Pharmacokinetics of clonidine and its relation to the hypotensive effect in patients. Br J Clin Pharmacol 6: 227–232
Wing, LMH, Reid JL, Davies DS, Neill EAM, Tippett P, Dollery CT (1977) Pharmacokinetics and concentration-effect relationships of clonidine in essential hypertension. Eur J Clin Pharmacol 12: 463–469
Davies DS, Wing LMH, Reid JL, Neill E, Tippett P, Dollery CT (1977) Pharmacokinetics and concentration-effect relationships of intravenous and oral clonidine. Clin Pharmacol Ther 21: 593–601
Schmidt H (1977) The pharmacology of clonidine and related products. In: Gross F (ed) Handbook of experimental pharmacology, Vol. 39, Chap 7, Springer, Berlin Heidelberg New York
Blaschke TF, Melmon KL (1980) Antihypertensive agents and the drug therapy of hypertension. In: Goodman, Gillman's (eds) The pharmacological basis of therapeutics, 6th edn. Chap 32. Macmillan, New York
Lowenthal DT (1980) Pharmacokinetics of clonidine. J Cardiovasc Pharmacol 2 [Suppl. 1]; 29–37
Frisk-Holmberg M, Edlund PO, Paalzow L (1980) Clonidin's kinetics and therapeutic effect during single and multiple dosage. VII World Conference on Clinical Pharmacology and Therapeutics, London 3rd-9th August 1980 Abstract No. 0274
Frisk-Holmberg M, Paalzow L, Edlund PO (1981) Clonidine kinetics in man — evidence for dose dependency and changed pharmacokinetics during clinic therapy. Br J Clin Pharmacol 12: 653–658
Arndts D, Warnkross H, Rominger KL, Justus H (1981b) Proof of the linearity of the pharmacokinetics of alinidine in man. Eur J Clin Pharmacol 21: 201–207
Peuler JD, Johnson GA (1977) Simultaneous single isotope radioenzymatic assay of plasma norepinephrine, epinephrine and dopamine. Life Sci 21: 625–636
Gundert-Remy U, Weber E (1976) Different pattern of excretion of14C-clonidine in rats after interuption of enterohepatic circulation. Naunym Schmiedebergs Arch Pharmacol 293 [Suppl 293]: R47
Magometschnigg D, Bonelli J, Gassner A, Hitzenberger G, Lenzhofer R, Kleinberger G, Pall H (1982) Duration of the hypotensive effect of guanfacine. Int J Clin Pharmacol Ther Toxicol 20: 174–178
Hansson L, Hunyor SN, Julius S, Hoobler SW (1973) Blood pressure crisis following withdrawal of clonidine (Catapres, Catapresan), with special reference to arterial and urinary catecholamine levels, and suggestions for acute management. Am Heart J 85: 605–610
Strauss FG, Franklin SS, Lewin AJ, Maxwell MH (1977) Withdrawal of antihypertensive therapy. Hypertensive crisis in renovascular hypertension. J Am Med Assoc 238: 1734–1736
Darda S (1975) Pharmacokinetics of clonidine. In: Milliez P, Safar M (eds) Recent advances in hypertension. Société Aliéna, Reims, Vol 2: pp 375–388
Draffan GH, Clare RA, Murray S, Bellward GD, Davies DS, Dollery CT (1976) The determination of clonidine in human plasma. Adv Mass Spectrom Biochem Med 2: 389–394
Edlund PO, Paalzow LK (1977) Quantitative gas-liquid-chromatographic determination of clonidine in plasma. Acta Pharmacol Toxicol 40: 145–152
Chu LC, Bayne WF, Tao FT, Schmitt LG, Shaw JE (1979) Determination of submicrogram quantities of clonidine in biological fluids. J Pharm Sci 68: 72–74
Weber MA (1980) Discontinuation syndrome following cessation of treatment with clonidine and other antihypertensive agents. J Cardiovasc Pharmacol 2 [Suppl. 1]: 73–89
Anderson RJ, Ram CVS, Kaplan NM (1979) Abrupt discontinuation of clonidine therapy: Monitoring the blood pressure changes in outpatients with a semi-automatic blood pressure recording device. Clin Res 27: 311A
Darda S, Förster H-J, Stähle H (1978) Metabolischer Abbau von Clonidin. Arzneim Forsch (Drug Res) 28: 255–259
Darda S, Förster H-J, Stähle H (1978b) Metabolic degradation of clonidine. Naunyn Schmiedebergs Arch Pharmacol 302 [Suppl]: R10
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Arndts, D., Doevendans, J., Kirsten, R. et al. New aspects of the pharmacokinetics and pharmacodynamics of clonidine in man. Eur J Clin Pharmacol 24, 21–30 (1983). https://doi.org/10.1007/BF00613922
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00613922